Eicosapentaenoic acid and docosahexaenoic acid modulate MAP kinase enzyme activity in human T-cells
Monitoring Mental Health During Treatment Initial Assessment and Regular Monitoring When it comes to managing mental health risks associated with semaglutide and tirzepatide, careful monitoring is a must
Tirzepatide microdosing opens the door to dual-receptor GLP-1/GIP therapy for patients who might not be candidates for, or interested in, full-dose treatment
GLP-1s are unlikely to deliver therapeutic value when so many individuals stop treatment after two years, but the findings also illustrate the need for obesity care management programs to improve adherence. Prime/MRx has been at the forefront of GLP-1 insights since we released our year-one research, and though we continue to see declines in persistence and adherence, we are committed to providing clients with actionable data and insights that can steer positive health outcomes for individuals. David Lassen, chief clinical officer David Lassen, chief clinical officer While real-world data is central to discussions about affordability and access, especially as the popularity of GLP-1 drugs for weight loss continues to climb, so too are comprehensive management strategies
I am really excited
After the injection site was changed to the arm, symptoms resolved completely
